Patients who initiated single inhaler triple therapy had improved inhaler adherence and persistence as compared to the initiation of multiple-inhaler triple therapy, suggests a recent real-world study. The study analysed 2,782 COPD patients who initiated triple therapy with fluticasone furoate, umeclidinium and vilanterol to find that single-inhaler triple therapy users were also twice as likely to be adherent to their inhaler treatment as compared to multiple-inhaler triple-therapy. Stressing on the advantages of single inhaler therapy, the researchers wrote that they examined further data from larger cohorts at different time periods. The study also highlighted that the likelihood of adherence as the proportion of days covered was 0.5 or more compared with multiple-inhaler triple therapy users.